drugset / Trial / NCT07085806

To Study Effect of Injection Pentoxifylline on Liver Growth After Major Liver Surgery

NCT07085806

RandomizedParallel-groupOpen-labelPrevention

Summary

Posthepatectomy liver failure (PHLF) remains a significant life-threatening problem after major hepatectomies. Pentoxifylline is shown to have potent vasodilating properties for peripheral blood vessels, along with the hepatic vasculature. In a Double-blinded, randomized, controlled trial (RCT) at a single tertiary care center (2006-2009) by Petrowsky, Henrik et al (Annals of Surgery, November 2010) on 101 Non-cirrhotic patients undergoing major Hepatectomy, they demonstrated beneficial effects of Pentoxifylline on regeneration of small remnant livers (RLBW ratio ≤ 1.2%). In mice model, pentoxifylline (Tian, Yinghua, et al Proceedings of the National Academy of Sciences 103.12 (2006)) is shown to confer protective effects against small-for-size syndrome in arterialized small-for-size liver transplantation. This Randomised control trial is being conducted to analyze the effect of Pentoxifylline supplementation in live donors undergoing donor hepatectomy with respect to markers of anatomical regeneration in a high volume liver transplant center in India.

Timeline

Start
2025-01-01
Primary completion
2025-07-15
Completion
2025-07-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Pentoxifylline Small molecule 1 mg/kg Intravenous

Indications

No indication recorded.